MX2022002297A - Receptores de citocinas quimericos que comprenden dominios de union al tgf beta. - Google Patents

Receptores de citocinas quimericos que comprenden dominios de union al tgf beta.

Info

Publication number
MX2022002297A
MX2022002297A MX2022002297A MX2022002297A MX2022002297A MX 2022002297 A MX2022002297 A MX 2022002297A MX 2022002297 A MX2022002297 A MX 2022002297A MX 2022002297 A MX2022002297 A MX 2022002297A MX 2022002297 A MX2022002297 A MX 2022002297A
Authority
MX
Mexico
Prior art keywords
cytokine receptors
tgf
chimeric cytokine
binding domains
tgf beta
Prior art date
Application number
MX2022002297A
Other languages
English (en)
Inventor
Blarcom Thomas John Van
Barbra Johnson Sasu
Siler Panowski
Regina Junhui Lin
Shanshan Lang
Original Assignee
Allogene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allogene Therapeutics Inc filed Critical Allogene Therapeutics Inc
Publication of MX2022002297A publication Critical patent/MX2022002297A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464404—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

En la presente descripción se proporcionan receptores de citocinas quiméricos que portan un dominio de unión capaz de unirse a un ligando TGF-ß o un anticuerpo contra el receptor del TGF-ß. Cuando están presentes en células inmunitarias que portan el receptor de antígeno quimérico (CAR) (células CAR-T), tales receptores permiten un aumento de la expansión, actividad y persistencia de las células CAR-T, constitutivamente y/o a través del acoplamiento de un ligando TGF-ß o un anticuerpo contra el receptor del TGF-ß. También se proporcionan métodos para fabricar y usar los receptores de citocinas quiméricos descritos en la presente descripción.
MX2022002297A 2019-08-30 2020-08-28 Receptores de citocinas quimericos que comprenden dominios de union al tgf beta. MX2022002297A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962894658P 2019-08-30 2019-08-30
US202063053322P 2020-07-17 2020-07-17
PCT/US2020/048402 WO2021041806A1 (en) 2019-08-30 2020-08-28 Chimeric cytokine receptors comprising tgf beta binding domains

Publications (1)

Publication Number Publication Date
MX2022002297A true MX2022002297A (es) 2022-03-25

Family

ID=72521701

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002297A MX2022002297A (es) 2019-08-30 2020-08-28 Receptores de citocinas quimericos que comprenden dominios de union al tgf beta.

Country Status (11)

Country Link
US (1) US20210061881A1 (es)
EP (1) EP4021582A1 (es)
JP (1) JP2022545167A (es)
KR (1) KR20220052919A (es)
CN (1) CN114341193A (es)
AU (1) AU2020336131A1 (es)
BR (1) BR112022003553A2 (es)
CA (1) CA3145614A1 (es)
IL (1) IL290960A (es)
MX (1) MX2022002297A (es)
WO (1) WO2021041806A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220023346A1 (en) 2020-07-21 2022-01-27 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
WO2023027561A1 (ko) 2021-08-27 2023-03-02 세라노틱스(주) B7-h3 및 tgfβ에 특이적으로 결합하는 이중 특이적 분자 및 이의 용도
WO2023056296A1 (en) * 2021-09-29 2023-04-06 Vita Therapeutics, Inc. Methods and compositions for treating cancer with engineered cells
GB202117298D0 (en) * 2021-11-30 2022-01-12 Quell Therapeutics Ltd Signalling protein
WO2023192895A1 (en) 2022-03-29 2023-10-05 Allogene Therapeutics Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
MA41538A (fr) * 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
BR112017015453A2 (pt) 2015-01-26 2018-01-23 Cellectis células imunes modificadas knockout para receptor de células t, dotadas de receptores quiméricos de antígeno, de ligação a cd123 para o tratamento de linfoma mieloide agudo recorrente/refratário ou neoplasia blástica de células dendríticas plasmacitoides
GB201522097D0 (en) * 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
CN116970630A (zh) * 2016-08-26 2023-10-31 贝勒医学院 用于细胞治疗的组成型活性细胞因子受体
AU2017362484B2 (en) * 2016-11-17 2021-12-16 2Seventy Bio, Inc. TGFβ signal convertor
WO2019118508A1 (en) * 2017-12-12 2019-06-20 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting ny-eso-1 and methods of use thereof

Also Published As

Publication number Publication date
IL290960A (en) 2022-04-01
CN114341193A (zh) 2022-04-12
WO2021041806A1 (en) 2021-03-04
US20210061881A1 (en) 2021-03-04
BR112022003553A2 (pt) 2022-05-24
EP4021582A1 (en) 2022-07-06
KR20220052919A (ko) 2022-04-28
JP2022545167A (ja) 2022-10-26
CA3145614A1 (en) 2021-03-04
AU2020336131A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
MX2022002297A (es) Receptores de citocinas quimericos que comprenden dominios de union al tgf beta.
MX2021010444A (es) Receptores de citocinas quimericos que tienen un ectodominio de pd-1.
MX2021010443A (es) Receptores de citocinas quimericos constitutivamente activos.
WO2019147805A3 (en) Regulatory t cells targeted with chimeric antigen receptors
MX2020009272A (es) Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
CO2020016586A2 (es) Diversos dominios de enlace de antígenos, nuevas plataformas y otras mejoras para terapia celular
CO2018001405A2 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple
EP4249068A3 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
MX2019013033A (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.
MX2020010241A (es) Composiciones de inmunoterapia celular y usos de las mismas.
ATE450549T1 (de) Monoklonale antikörper mit spezifität für fetale erythroidzellen
TR201905437T4 (tr) İki işlevli polipeptidler.
MX2020009463A (es) Receptor de antígeno quimérico de receptor de il-13 alfa 2 (il13ra2) para inmunoterapia de células t específica para tumor.
MX2021009722A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
Lloyd et al. Immunohistochemical localization of chromogranin in human hypophyses and pituitary adenomas.
ZA202206438B (en) Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
PH12020500632A1 (en) Cd83-binding chimerix antigen receptors
EP3973000A4 (en) HIGH AFFINITY ANTI-CD3 ANTIBODIES AND METHODS OF GENERATION AND USE THEREOF
WO2021048564A3 (en) Antigen-binding domain
EP4031150A4 (en) CD70-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AND USES THEREOF
MX2022007404A (es) Materiales y metodos para direccionamiento biologico in vivo.
IL304588A (en) Anti-pd-l1 monoclonal antibodies and proteins fused to interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2
ATE279443T1 (de) A3c6e2, ein monoklonaler antikörper spezifisch für den humanen stammzellfaktor (scf)-rezeptor
MX2021002750A (es) Anticuerpos anti-tnfrsf9 y usos de los mismos.
WO2020065330A3 (en) Chimeric antigen receptor